BML-190
(Synonyms: 吲哚美辛吗啉代酰胺; Indomethacin morpholinylamide; IMMA) 目录号 : GC11376A CB2 receptor inverse agonist
Cas No.:2854-32-2
Sample solution is provided at 25 µL, 10mM.
BML-190(IMMA) is a potent and selective CB2 receptor ligand (Ki values = 435 nM)
The cannabinoid receptor (CB1 and CB2) is a member of G-protein coupled receptor (GPCR) which plays a significant role in physiologic processes such as cognitive and immune functions.
In HEK-293 cells expressing human Cb2 receptor, BML-190 promoted the forskoline-stimulated accumulation of cAMP. BML-190 also reduced the basal level production of inositol phosphate the CB(2) receptor and 16z44-expressing cells. [1]
BML-190 played a role in LPS (lipopolysaccharide)-activated inflammation [2] and in lowering human cytokine secretion and monocytic cell neurotoxicity [3]. It activated fibroblastic colony formation [4] and moderated collagen-induce arthritis [5].
References:
[1] New DC, Wong YH. BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates. FEBS Lett. 2003 Feb 11;536(1-3):157-60. PubMed PMID: 12586356.
[2] Chang YH, Lee ST, Lin WW. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J Cell Biochem. 2001;81(4):715-23. PubMed PMID: 11329626.
[3] Klegeris A, Bissonnette CJ, McGeer PL. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol. 2003 Jun;139(4):775-86. PubMed PMID: 12813001; PubMed Central PMCID: PMC1573900.
[4] Scutt A, Williamson EM. Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcif Tissue Int. 2007 Jan;80(1):50-9. Epub 2007 Jan 4. PubMed PMID: 17205329.
[5] Zhang L, Zhang X, Wu P, Li H, Jin S, Zhou X, Li Y, Ye D, Chen B, Wan J. BML-111, a lipoxin receptor agonist, modulates the immune response and reduces the severity of collagen-induced arthritis. Inflamm Res. 2008 Apr;57(4):157-62. doi: 10. 1007/s00011-007-7141-z. PubMed PMID: 18648754.
[6] Zhang Q, Ma P, Cole RB, Wang G. In vitro metabolism of indomethacin morpholinylamide (BML-190), an inverse agonist for the peripheral cannabinoid receptor (CB(2)) in rat liver microsomes. Eur J Pharm Sci. 2010 Sep 11;41(1):163-72. doi: 10.1016/j.ejps.2010.06.004. Epub 2010 Jun 11. PubMed PMID: 20542112; PubMed Central PMCID: PMC2907062.
Cas No. | 2854-32-2 | SDF | |
别名 | 吲哚美辛吗啉代酰胺; Indomethacin morpholinylamide; IMMA | ||
化学名 | 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-1-morpholin-4-ylethanone | ||
Canonical SMILES | CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)N4CCOCC4 | ||
分子式 | C23H23ClN2O4 | 分子量 | 426.89 |
溶解度 | ≥ 42.7mg/mL in DMSO with gentle warming | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.3425 mL | 11.7126 mL | 23.4252 mL |
5 mM | 0.4685 mL | 2.3425 mL | 4.685 mL |
10 mM | 0.2343 mL | 1.1713 mL | 2.3425 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet